Ear2 Deletion Causes Early Memory and Learning Deficits in APP/PS1 Mice

Markus P. Kummer, University of Bonn
Thea Hammerschmidt, University of Bonn
Ana Martinez, Max Planck Institute of Biophysical Chemistry
Dick Terwel, University of Bonn
Gregor Eichele, Max Planck Institute of Biophysical Chemistry
Anika Witten, Leibniz-Institut für Arterioskleroseforschung
Stefanie Figura, Leibniz-Institut für Arterioskleroseforschung
Monika Stoll, Leibniz-Institut für Arterioskleroseforschung
Stephanie Schwartz, University of Bonn
Hans-Christian Pape, Westfälische Wilhelms-University Münster

Only first 10 authors above; see publication for full author list.

Journal Title: Journal of Neuroscience
Volume: Volume 34, Number 26
Publisher: Society for Neuroscience | 2014-06-25, Pages 8845-8854
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1523/JNEUROSCI.4027-13.2014
Permanent URL: https://pid.emory.edu/ark:/25593/s2tsk

Final published version: http://dx.doi.org/10.1523/JNEUROSCI.4027-13.2014

Copyright information:
© 2014 the authors.
This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License (http://creativecommons.org/licenses/by-nc-sa/3.0/).

Accessed January 2, 2019 8:44 PM EST
To assess the consequences of locus ceruleus (LC) degeneration and subsequent noradrenaline (NA) deficiency in early Alzheimer’s disease (AD), mice overexpressing mutant amyloid precursor protein and presenilin-1 (APP/PS1) were crossed with Ear2(−/−) mice that have a severe loss of LC neurons projecting to the hippocampus and neocortex. Testing spatial memory and hippocampal long-term potentiation revealed an impairment in APP/PS1 Ear2(−/−) mice, whereas APP/PS1 or Ear2(−/−) mice showed only minor changes. These deficits were associated with distinct synaptic changes including reduced expression of the NMDA 2A subunit and increased levels of NMDA receptor 2B in APP/PS1 Ear2(−/−) mice. Acute pharmacological replacement of NA by L-threo-DOPS partially restored phosphorylation of β-CaMKII and spatial memory performance in APP/PS1 Ear2(−/−) mice. These changes were not accompanied by altered APP processing or amyloid β peptide (Aβ) deposition. Thus, early LC degeneration and subsequent NA reduction may contribute to cognitive deficits via CaMKII and NMDA receptor dysfunction independent of Aβ and suggests that NA supplementation could be beneficial in treating AD.

**Key words**: Alzheimer; locus ceruleus; memory; neurodegeneration; noradrenaline

**Introduction**

Alzheimer’s disease (AD) is the most common cause of dementia characterized by the deposition of the amyloid β peptide (Aβ) in senile plaques and progressive memory loss (Querfurth and LaFerla, 2010). The degeneration of the locus ceruleus (LC), located within the brain stem, is an early event in AD pathogenesis (Forno, 1966). Loss of LC neurons has even been observed in patients suffering from mild cognitive impairment that are at high risk for developing AD over the next decade (Grudzien et al., 2007). The LC consists of approximately 1700 neurons and is divided in a dorsal and a ventral part (Swanson, 1976). The dorsal part projects mostly into the neocortex, where it serves as the sole source of noradrenaline (NA). In addition to direct synaptic transmission, NA influences distant neurons, glial cells, and blood vessels when released from extrasynaptic varicosities (Marien et al., 2004).

Functionally, the LC is involved in the modulation of general arousal, selective attention, learning and memory, stress reactivity, behavioral adaptation, sleep architecture, and inflammation (Sara, 2009). During normal aging, LC neurons and cerebral NA concentrations decline by 25–50%. Some memory tasks may be rescued by activation of the noradrenergic system (Marien et al., 2004). LC neuron loss correlates well with Aβ plaque load and the severity of dementia and is more abundant and corresponds better to AD progression than the degeneration of the nucleus basalis of Meynert (Zarow et al., 2003). There is evidence that LC changes may be an initial event in AD pathogenesis, since LC cell loss does not result from nonspecific retrograde degenerative processes (Marien et al., 2004).

One animal model, to investigate the impact of the LC on AD-like neuropathology, is the application of the neurotoxin N-[2-chloroethyl]-N-ethyl-2-bromobenzylamine (DSP-4) causing the specific destruction of LC neurons (Heneka et al., 2006; Kalinin et al., 2007; Hurko et al., 2010; Jardanhazi-Kurutz et al., 2010). Since LC neurons produce, besides NA, a variety of other neuromodulators, DSP-4 lesions may not isolate the contribu-
Figure 1. LC degeneration and noradrenergic deficit in LC projection areas. A, Time scheme of the different experiment and analysis conducted. IHC, Immunocytochemistry. B, TH in situ hybridization of wt, APP/PS1, Ear2(/-/-), and APP/PS1 Ear2(/-/-) mice. Loss of Ear2 causes a strong reduction of TH-positive neurons in the dorsal part of the LC (scale bars, 200 μm). C, Determination of NA level in the olfactory bulb (OB), frontal cortex (FC), hippocampus (HC), and cerebellum (CB) by HPLC in 4-month-old wt, APP/PS1, Ear2(/-/-), and APP/PS1 Ear2(/-/-) mice (mean of n = 4–5 ± SEM; two-way ANOVA, Bonferroni’s post-test; see Table 1). D, Same as B but in 12-month-old mice (mean of n = 4–5 ± SEM; two-way ANOVA, Bonferroni’s post-test; see Table 1). E, Quantification of the GFAP-positive area in the frontal cortex of wt, Ear2(/-/-), APP/PS1, and APP/PS1 Ear2(/-/-) mice at 5 months of age (mean of n = 4–5 mice ± SEM; 4 sections per mouse; one-way ANOVA followed by Tukey’s post hoc test, *p < 0.05, ***p < 0.001). F, Representative images of GFAP-stained wt, Ear2(/-/-), APP/PS1, and APP/PS1 Ear2(/-/-) mice analyzed in E (scale bars, 500 μm).
tion of NA loss itself. Recently, we described a model where NA production was completely abolished by the deletion of the enzyme dopamine β-hydroxylase catalyzing the conversion of dopamine to NA, revealing cognitive deficits and changes in learning-associated proteins (Hammerschmidt et al., 2013).

Nevertheless, the consequences of early LC degeneration on AD remain unclear (Weinshenker, 2008). Since mouse models of AD show only very limited deficits regarding the LC, and do not appear until long after profound forebrain neuropathology is evident (O’Neil et al., 2007), we aimed to assess consequences of early LC loss.

We therefore crossed amyloid precursor protein and presenilin-1 (APP/PS1) mice with mice lacking the orphan nuclear receptor Ear2 (also known as Nrl2if6), which is necessary for the development of LC neurons in mice. Loss of Ear2 primarily affects its dorsal division, which projects to the neocortex and hippocampus (Warnecke et al., 2005). Wild-type (wt), APP/PS1, Ear2(−/−), and APP/PS1 Ear2(−/−) mice were tested for spatial memory, synaptic plasticity, APP processing, inflammatory reaction, and synaptic protein abundance (Fig. 1A).

Materials and Methods

**Animals.** Hemizygous APP/PS1 mice expressing a chimeric mouse/human APP with the Swedish mutation and a human PS1 Aexon 9 mutation (Jankowsky et al., 2001) were studied. Ear2(−/−) mice were generated as described previously (Warnecke et al., 2005). All animals were maintained on a C57BL/6 background. Mice were housed in groups under standard conditions at a temperature of 22°C and a 12 h light/dark cycle with *ad libitum* access to standard food (Altromin) and water. Gender-balanced groups were used for the *in situ* hybridization, the NA quantification, and the behavioral experiments. For all other experiments, either female or male mice were used. For dissection, mice were killed by deep anesthesia using isoflurane and perfused with 20 ml of PBS through the heart using a peristaltic pump. The skull was removed, and the brain was split into hemispheres. The cerebellum was removed, and the remaining forebrain was immediately frozen on dry ice and stored at −80°C. The other hemisphere was fixed in 4% paraformaldehyde. Animal care and handling were performed according to the Declaration of Helsinki and approved by local ethical committees.

**Quantification of NA concentration by HPLC.** Specific brain regions were dissected, weighed, and homogenized in 100, 200, or 300 μl of sample buffer (0.1 M perchloric acid, 0.01% EDTA, and 0.08 ng/μl 3,4-dihydroxybenzylamine, used as an internal standard). Twenty microliters of the sample was injected onto a C18 reverse-phase column (Spherisorb ODS-1, 5 μm, 250 × 4.6 mm; Teclab). The isotropic mobile phase consisted of 0.15 M chloroacetic acid, 0.2 mM EDTA, 0.86 mM sodium octyl sulfate, 6% acetonitrile, and 2.5% tetrahydrofuran, pH 3, at a flow rate of 1.2 ml/min. NA was detected by an electrochemical detector (Coulouchem II, model 5200A; ESA).

**In situ hybridization for tyrosine hydroxylase.** The procedure for *in situ* hybridization has been described previously (Yaylaoglu et al., 2005). The following tyrosine hydroxylase (TH)-specific (NM_009377) PCR primers were used: forward 5'-GATTGCGAGAGAGTGCCTTC-3' and reverse 5'-CCTTGTGGGTGTACCCATG-3'. The 2100 Bioanalyzer (Agilent) was used for quantification.

**Drugs and treatments.** For the 1-3-, 3,4-dihydroxyphenylserine (DOPS) rescue experiments, male APP/PS1 Ear2(−/−) mice were given injections each day of the Morris water maze (MMW) and were tested 5 h after injection, when brain NA levels peak (Thomas et al., 1998). The injection contained DOPS (500 mg/kg, s.c.), benzeradize (125 mg/kg, s.c.), and ascorbic acid (2 mg/ml). Control mice were treated with the corresponding volume of vehicle solution. Because DOPS is converted to NA by the enzyme aromatic acid decarboxylase (AADC) and benzeradize is almost completely absorbed across the blood–brain barrier, DOPS plus benzeradize treatment selectively restores NA in the brain (Thomas et al., 1998; Murchison et al., 2004).

**Table 1. Statistical analysis of noradrenaline concentrations in 4- and 12-month-old mice (see Fig. 1C,D)**

<table>
<thead>
<tr>
<th>Comparison</th>
<th>Brain area</th>
<th>4 month <em>p</em> value</th>
<th>12 month <em>p</em> value</th>
</tr>
</thead>
<tbody>
<tr>
<td>wt vs APP/PS1</td>
<td>OB</td>
<td>n.s.</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td></td>
<td>FC</td>
<td>n.s.</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td></td>
<td>HC</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>CB</td>
<td>n.s.</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>wt vs Ear2(−/−)</td>
<td>OB</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>FC</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>HC</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>CB</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>APP/PS1 vs Ear2(−/−)</td>
<td>OB</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>FC</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>HC</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>CB</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>APP/PS1 vs APP/PS1 Ear2(−/−)</td>
<td>OB</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>FC</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>HC</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>CB</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Ear2(−/−) vs APP/PS1 Ear2(−/−)</td>
<td>OB</td>
<td>n.s.</td>
<td>n.s.</td>
</tr>
<tr>
<td></td>
<td>FC</td>
<td>n.s.</td>
<td>n.s.</td>
</tr>
<tr>
<td></td>
<td>HC</td>
<td>n.s.</td>
<td>n.s.</td>
</tr>
<tr>
<td></td>
<td>CB</td>
<td>n.s.</td>
<td>n.s.</td>
</tr>
</tbody>
</table>

*Two-way ANOVA followed by Bonferroni’s post hoc test.

**Behavioral analysis.** Mice were singly housed in the testing room under a reversed light/dark cycle for 2 weeks before the start of behavioral experiments. Approximately equal numbers of male and female mice at the age of 4 months were used, before plaque deposition. Behavior was scored by an observer blind to the genotype and treatment groups. For the open-field (OF) exploration, mice were placed in the center of the dimly lit (20–30 lux) open field arena (61 × 61 × 61 cm). Movements of the animals were tracked by an automatic monitoring system (Ethovision 3; Noldus) for 5 min. The area was virtually divided into a center (40 cm edge lengths), a corridor (7.5 cm along the walls), and four corner squares (with 10 cm edge lengths). The experiment was repeated on 3 consecutive days. The WMW test was conducted in a circular tank (15, 1 m) filled with opacified water at 24°C. The water basin was dimly lit (20–30 lux) and surrounded by a white curtain. The maze was virtually divided into four quadrants. In one of the quadrants, a hidden platform (15 × 15 cm) was present 1.5 cm below the water surface. Mice were trained to find the platform by means of three intermediate cues placed asymmetrically at the walls of the tank. They were let into the water in a quasi-random fashion to prevent strategy learning. Mice were allowed to search for the platform for 40 s. Mice that did not reach the platform in the allotted time were placed manually on it and stayed there for 15 s. Mice received four training trials per day for 8 consecutive days. Movements of the mice were recorded by a tracking system (Ethovision 3; Noldus). On the ninth day, the mice were tested for latency to find the cued/visual platform.

**Long-term potentiation in vitro.** Electrophysiological recordings were performed on brain slices from 4-month-old male mice. Brains were sliced sagittally in 400 μm sections using a Vibratome (Integralslice 7550 PSDK; Camden Instruments). Hippocampal slices were isolated and maintained at 29°C in an oxygen-enriched atmosphere in artificial CSF (aCSF; containing 124 mM NaCl, 4 mM KCl, 1.24 mM NaH2PO4, 1.3 mM MgSO4, 26 mM NaHCO3, 10 mM D-glucose, and 1 mM CaCl2) for 30 min, followed by incubation in aCSF at elevated CaCl2 (2 mM) for an additional 30 min. Extracellular field EPSPs (fEPSPs) were recorded in the pyramidal cell layer of the cornu ammonis 1 (CA1) region using glass microelectrodes (resistance, 0.7–2 MΩ) filled with aCSF. The stimulating electrode was placed in the CA2 region within the Schaffer collaterals. Stimuli were applied at a constant current at a duration of 0.1 ms. The
Table 2. Statistical analysis of the Morris water maze

<table>
<thead>
<tr>
<th>Factor</th>
<th>F value (time)</th>
<th>p value (time)</th>
<th>F value (distance)</th>
<th>p value (distance)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ear2(−/−)</td>
<td>F(1,16)= 5.67</td>
<td>*p&lt;0.05</td>
<td>4.32</td>
<td>*p&lt;0.05</td>
</tr>
<tr>
<td>APP/PS1</td>
<td>F(1,16)= 2.99</td>
<td>p&gt;0.05</td>
<td>10.42</td>
<td>**p&lt;0.01</td>
</tr>
</tbody>
</table>

Data are intersubject effects of two-way ANOVA with repeated measurements.

initial slope of evoked fEPSPs was measured as an index of synaptic strength. Basal synaptic transmission was assessed by plotting the stimulus intensity (in microamps) against the peak slope of the evoked fEPSP. The LTP was induced by a theta stimulus intensity (in microamps) that evoked a response of ~30% of maximum fEPSP. The LTP was induced by a theta burst consisting of four trains of 10 pulses at 100 Hz separated by 200 ms.

**Extraction of brain lysates.** Extraction of forebrains from male mice was performed as described previously (Kummer et al., 2011). Briefly, snap-frozen forebrain hemispheres were homogenized in PBS, and protein was extracted in RIPA (25 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.5% sodium deoxycholate, 1% NP-40, and 0.1% SDS). After centrifugation at 100,000 g for 30 min at 4°C, the supernatant (RIPA-soluble fraction) was saved, and the pellet was sonified in 25 mM Tris-HCl, pH 7.5, and 2% SDS (RIPA-insoluble fraction).

**Synaptosomal preparation.** Forebrains of male mice were homogenized in 9 volumes of 0.32 M sucrose buffer (50 mM Tris acetate, 1 mM EDTA, 5 mM pyrophosphate, 5 mM NaF, 2 mM Na$_2$VO$_4$, 1 mM PMSE, and protease inhibitor mixture, pH 7.4) using a Teflon-glass homogenizer (0.15 mm clearance) at 700 rpm, and homogenates were centrifuged at 800 g for 15 min. The supernatant was layered on a discontinuous sucrose density gradient consisting of 1.4 and 1.0 M sucrose and centrifuged at 54,000 X g for 90 min, and the synaptosomal fraction was recovered from the interface of the 1.4 and 1.0 M sucrose layers, diluted with H$_2$O, and centrifuged at 17,000 X g for 15 min.

**Western blot analysis of brain extracts and synaptosomal fractions.** Protein concentrations were determined using the BCA Protein Assay kit (Pierce). Protein samples were separated by 4–12% NuPAGE (Invitrogen) using MES or 3-(N-morpholino) propanesulfonic acid buffer and transferred to nitrocellulose membranes. For detection of Aβ, blots were boiled 5 min in water. Aβ was detected using antibody 6E10 (catalog #SIG-39300-500 RRID:AB_10175291; Covance), APP and C-terminal fragment (CTF) using antibody C-terminal 140 (kind gift from Dr. J. Walter, University of Bonn, Bonn, Germany), BDNF using antisera sc-546 (catalog #sc-546 RRID:AB_630940; Santa Cruz Biotechnology), PS1 using antibody PS1-NT (catalog #529591 RRID:AB_2172922; EMD Biosciences) or polyclonal antibody 3109 (kind gift from Dr. J. Walter; Prager et al., 2007). Tubulin (catalog #7E7 RRID:AB_528499; Developmental Studies Hybridoma Bank) was used as a loading control. In synaptosomal fractions, protein levels of CaMKII (catalog #sc-9035 RRID:AB_634551; Santa Cruz Biotechnology), CaMKII T286 phosphorylation (catalog #PP5002 RRID:AB_2290672; R&D Systems), NR2A (catalog #454582-10UG RRID:AB_10690211; Merck), and NR2B (catalog #454582-10UG RRID:AB_10690211; Merck) were assessed. RabGDI dissociation inhibitor (GDI; catalog #130 011 RRID:AB_1966443; Sypnaptic Systems) was used as an internal control. Primary antibody incubation was followed by incubation with appropriate horseradish peroxidase-conjugated or infrared dye-coupled secondary antibodies. Immunoactivity was detected by enhanced chemiluminescence reaction (Millipore), and luminescence intensities were analyzed using the Chemidoc XR5 documentation system (Bio-Rad). In case of infrared dye-coupled secondary antibodies, signals were detected using the Odyssey Clx imaging system (Li-COR).

**Sandwich ELISA for Aβ.** 32 Quantitative determination of Aβ1–40 and Aβ1–42 from brain extracts was performed using the human Amyloid Aβ1–40 and Aβ1–42 ELISA kit (Millipore) according to the manufacturer’s instructions. Samples were cleared by centrifugation at 100,000 X g for 20 min and diluted to meet the concentration range of the standard curve.

**Histology.** Serial sagittal cryosections (40 μm) of male mice were immunostained free-floating using antisera against GFAP (catalog #Z0334 RRID:AB_10013382, 1:800; Dako). For that, sections were washed in PBS, permeabilized using PBST (PBST and 0.1% Tx-100), and blocked for 1 h in 20% goat serum in PBST. Primary antibodies were added in 10% goat serum on PBST for 18 h at 4°C while gently rocking.
Secondary antibodies were added to 10% goat serum in PBST for 1.5 h at room temperature. Sections were mounted with Immumount (Thermo Fisher Scientific) on supercool slides. Sections were analyzed using a BX61 microscope equipped with a disk-spinning unit (Olympus). Quantitative assessment of the stained areas was done using the Fiji-ImageJ 1.48p software bundle (ImageJ, RRID:nif-0000-30467).

Statistical analysis. Behavioral data of the MWM test were analyzed by two-way ANOVA with repeated measurements (independent between subjects variables: APP/PS1 transgene, Ear2(−/−) and DOPS treatment; dependent between subjects variables: latency or distance; independent within subject variable: day). If a significant effect of the independent variables was found in the ANOVA, the Student’s t test for intergroup comparison was performed subsequently. Statistical evaluation was done with SPSS 17 (RRID:rid_000042; IBM) and Prism 5.03 (RRID:rid_000081; GraphPad).

Results

NA reduction in LC projection areas by Ear2(−/−)

Ear2(−/−) caused a 70% loss of LC neurons (Warnecke et al., 2005), predominantly in the dorsal division (Fig. 1B; Warnecke et al., 2005), resulting in a 60–75% decrease of NA levels in projection areas like the hippocampus, frontal cortex, cerebellum, and olfactory bulb in 4- and 12-month-old Ear2(−/−) and APP/PS1 Ear2(−/−) mice (Fig. 1C,D; Table 1). We also observed a minor reduction of NA in the 12-month-old APP/PS1 mice compared with wild-type mice, demonstrating that the APP/PS1 transgenes already have a negative impact on NA production in the LC (Fig. 1D). Since NA has been described to suppress inflammation, we looked for indications of astrogliosis, an early symptom for neuroinflammation. Detection of GFAP by immunohistochemistry at 5 months of age revealed that APP/PS1 and APP/PS1 Ear2(−/−) mice have increased GFAP-positive areas over wt and Ear2(−/−) mice (Fig. 1E,F). In addition, APP/PS1 Ear2(−/−) mice show an even higher percentage of GFAP-positive areas compared with APP/PS1 mice, suggesting that partial loss of the LC and decreased NA concentration favor the occurrence of astrogliosis.

Ear2(−/−) increases cognitive deficits in APP/PS1 mice

Testing the exploration behavior in the OF test, Ear2(−/−) did not affect horizontal activity (Fig. 2A). The presence of the APP/PS1 transgene induced a slight hyperactivity (Fig. 2A). No differences in center time were observed between the genotypes, suggesting that Ear(−/−) deficiency does not influence anxiety-like behavior in this setup.

In the MWM test (Fig. 2B,C), all mice learned to find a hidden platform by spatial navigation. Two-way ANOVA with repeated measurements revealed differences for distance for the factors Ear2(−/−) and APP/PS1 and for latency for the factor APP/PS1 (Table 2). However, Ear2(−/−) and APP/PS1 Ear2(−/−) mice had increased escape latencies (Fig. 2B) and longer distances to platform (Fig. 2C) compared with wild-type controls. There was no difference between APP/PS1 and APP/PS1 Ear2(−/−). Testing the ability to find the visual platform on day 9 revealed a difference between wt and APP/PS1 Ear2(−/−) mice, but not between the APP/PS1 transgenic or Ear2(−/−) groups (Fig. 2D).

Loss of Ear2 impairs long-term but not short-term synaptic plasticity

Since synaptic plasticity is considered one of the major cellular mechanisms that underlies spatial memory formation, we recorded hippocampal LTP of CA1 neurons along the Schaffer collateral in vitro. fEPSPs were recorded in the pyramidal cell layer. Peak slopes of fEPSP recordings, averaged before and after LTP induction, were recorded (Fig. 3A). Early and late stages of LTP were assessed at 10 min (T1) and 60 min (T2) after induction, respectively. APP/PS1 and Ear2(−/−) mice showed a modest but significant reduction in the early (T1) and late (T2) components of LTP, compared with wt mice, but the ability to form LTP was strongly decreased in the APP/PS1 and APP/PS1 Ear2(−/−) mice (Fig. 3B,C).

Next, we assessed short-term synaptic plasticity by PPF in the CA1 region using varying interstimuli intervals. Changes in PPF during synaptic potentiation can indicate a change in the expression of synaptic proteins at the presynaptic site. PPF was similar in all genotypes tested (Fig. 3D). Furthermore, PPF was the same before and after LTP induction, suggesting that suppression of LTP was caused by changes at the postsynaptic site.
Ear2 modulates plasticity-related proteins at the synapse
To reveal why Ear2 deficiency causes reduced synaptic memory, synaptic fractions from all mice groups were analyzed for changes in learning-associated proteins (Fig. 4). We observed that phosphorylation levels at threonine 268 of α- and β-CaMKII were lower in APP/PS1 Ear2(−/−) independent on the overall expression of α- or β-CaMKII (Fig. 4); even so, this effect did not reach statistical significance. In addition, we found that Ear2 deficiency caused decreased expression of the NMDAR subunit NR2A in APP/PS1 Ear2(−/−) mice, whereas the NR2B subunit was upregulated (Fig. 4A,D,E).

DOPS partially rescues spatial memory impairment caused by loss of Ear2
To test whether acute NA restoration can revert spatial memory impairment in APP/PS1 Ear2(−/−) mice, the NA precursor DOPS was coadministered with benserazide, an inhibitor of the peripheral AADC. Since benserazide does not pass the blood–brain barrier, but DOPS, NA production was restricted to the brain (Thomas et al., 1998). MWM sessions were performed 5 h after DOPS treatment, a time when cerebral NA levels peak (Thomas et al., 1998). DOPS-treated APP/PS1 Ear2(−/−) mice showed improved performance in the MWM concerning distance compared with untreated APP/PS1 Ear2(−/−) littermates (Fig. 5A,B).

DOPS treatment increases phosphorylation of CaMKII in APP/PS1 Ear2(−/−) mice
To determine whether NA restoration changes β-p-CaMKII and NR2A/NR2B levels, we investigated potential alterations in APP/PS1 Ear2(−/−) mice treated with DOPS compared with APP/PS1 Ear2(−/−) mice. We observed that phosphorylation of β-CaMKII at threonine 286 was increased after DOPS treatment in APP/PS1 Ear2(−/−) mice (Fig. 5C,D).

Aβ deposition is not influenced by Ear2(−/−)
Because Aβ have been reported to affect synaptic function, LTP, and memory performance (Selkoe, 2008) and LC ablation by the neurotoxin DSP-4 increases Aβ levels (Heneka et al., 2006), APP processing and Aβ levels were analyzed at 4 months of age (before Aβ deposition in APP/PS1 mice; Fig. 6A–F) and at 12 months of age (an age at which Aβ deposition is high in APP/PS1 mice; Fig. 6H–L). APP expression levels were unchanged between wild-type and Ear2(−/−) mice and APP/PS1 Ear2(−/−) mice (Fig. 6B). There were no changes in the steady-state levels of β-CTF or α-CTF in the APP/PS1 transgenic groups (Fig. 6C,D). We did observe an increase in α-CTF between the wild-type and the Ear2(−/−) mice (Fig. 6C). Aβ levels were unaffected by the loss of Ear2(−/−) in the RIPA- and SDS-soluble pool in the APP/PS1 transgenic mice (Fig. 6F,G). Since
Aβ levels are unchanged, another LC-derived factor might be responsible for the memory loss caused by Ear2(−/−). We therefore determined the expression of BDNF, an important factor for memory formation, in these mice. Interestingly, we found that BDNF levels reduced in the APP/PS1 Ear2(−/−) mice (Fig. 6G).

Analysis in 12-month-old animals revealed no changes in APP expression (Fig. 6H, J), CTF/APP ratio (Fig. 6H, J), and Aβ levels in the RIPA- and SDS-soluble fractions (Fig. 6K–N) either. These results suggest that the increase in Aβ levels observed previously in DSP-4-treated mice is caused by pathways initiated in response to the acute loss of LC neurons or NA, a phenomenon that has not been mimicked by the present models, possibly because of compensatory mechanisms in genetic models of chronic NA deficiency.

Discussion

NA is involved in the behavioral changes in response to imperturbatives in the environment by modulating most stages of memory. We therefore hypothesized that perturbation of the NA system, caused by loss of LC neurons, could interfere with synaptic plasticity and memory formation (Sara, 2009). Previously, the selective destruction of the LC by the neurotoxin DSP-4 has been used to model LC degeneration in murine models of Alzheimer’s disease (Wenk et al., 2003; Heneka et al., 2006; Kalinin et al., 2007). DSP-4-induced LC degeneration has the disadvantage that the resulting neuronal cell death may create an inflammatory reaction within the LC and in the projection areas. We therefore aimed to generate a genetic model that mimics early neuronal LC loss in a mouse model of Alzheimer’s disease by cross-breeding APP/PS1 with Ear2(−/−) mice. In this model, we observed that loss of Ear2 causes a severe drop of NA in all investigated brain regions. In addition, we observed increased expression of GFAP in APP/PS1 Ear2(−/−) mice compared with APP/PS1 mice in the frontal cortex even before the onset of plaque deposition, suggesting that Ear2(−/−) affects the inflammatory status of astrocytes in LC projection areas. This increase of GFAP expression is in accordance with what has been observed for DSP-4 lesions in the APP23 model (Heneka et al., 2006).

Our behavioral data provide evidence that before plaque deposition, mice carrying the APP/PS1 transgene or lacking Ear2 were modestly impaired in the MWM, whereas APP/PS1 Ear2(−/−) mice, reflecting the AD patient’s situation, showed an additive effect and therefore a robust loss of spatial memory formation. Loss of spatial memory in mouse models based on APP overexpression has been described in detail previously (Zhang et al., 2006) and may be explained by findings that soluble Aβ oligomers interfere with cognition even before plaque deposition starts (Clery et al., 2005; Comery et al., 2005; Saura et al., 2005). The results of the present study indicate that LC degeneration and the subsequent reduction of NA levels in its projection areas may worsen spatial memory, either on its own or in combination with Aβ. Spatial memory deficits caused by Ear2 deficiency were partially rescued by NA supplementation with l-threo DOPS.
Figure 6. Analysis of APP processing in 4- and 12-month-old mice. A, Four-month-old wt, Ear2(−/−), APP/PS1, and APP/PS1 Ear2(−/−) mice were analyzed by Western blot using antiserum 140 for APP and CTF, antibody 6E10 for sAPP/APP and β-CTF, antiserum sc-546 for BDNF, and antibody E7 for tubulin. B, Quantification of the APP levels from A normalized to tubulin (mean of $n = 4 \pm SEM$; one-way ANOVA, ***$p < 0.001$). C, Quantification of the CTF/APP ratios from A using APP C-terminal antiserum 140 (mean of $n = 4 \pm SEM$; one-way ANOVA, ***$p < 0.001$). D, Quantification of the β-CTF/APP ratios from A using antibody 6E10 (mean of $n = 4 \pm SEM$; Student’s t-test). E, F, ELISA analysis of RIPA-extractable Aβ40 (E) and SDS-extractable (F) Aβ40 and Aβ42 (mean of $n = 6 \pm SEM$; Student’s t-test). G, Quantification of the BDNF levels from A normalized to tubulin (mean of $n = 4 \pm SEM$; one-way ANOVA, ***$p < 0.001$). H, Twelve-month-old wt, APP/PS1, Ear2(−/−), and APP/PS1 Ear2(−/−) mice were analyzed by Western blot using antiserum 140 for APP, antibody 6E10 for sAPP/APP and β-CTF, and antibody E7 for tubulin. I, Quantification of the APP levels from H normalized to tubulin (mean of $n = 5–6 \pm SEM$; Student’s t-test). J, Quantification of the β-CTF/APP ratios from H (mean of $n = 5–6 \pm SEM$; Student’s t-test). K, L, ELISA analysis of RIPA-extractable Aβ40 (K) and Aβ42 (L; mean of $n = 5–6 \pm SEM$; Student’s t-test). M, N, ELISA analysis of SDS-extractable Aβ40 (M) and Aβ42 (N; mean of $n = 5–6 \pm SEM$; Student’s t-test).
We and others have previously shown that acute reductions of forebrain NA levels increased Aβ deposition (Heneka et al., 2006; Hammerschmidt et al., 2013). Surprisingly, we did not observe any changes of APP processing or Aβ levels in 4- or 12-month-old APP/PS1 Ear2(−/−) mice. Multiple differences between the DSP-4 and the Ear2(−/−) models may account for this observation. Thus, the genetic LC loss may have induced changes within the affected LC projection areas that compensate for the loss of NA. Alternatively, DSP-4-caused acute LC cell death may lead to the induction of inflammatory brain responses, which increases Aβ deposition and/or impairs its clearance.

Additional studies are needed to elucidate when and why LC dysfunction and degeneration occurs in AD. If memory decline in AD is aggravated by LC degeneration and subsequent loss of NA, replenishment of NA levels may provide therapeutic benefit.

References


Lamsa K, Irvine EE, Giese KP, Kullmann DM. (2007) NMDA receptor-dependent long-term potentiation in mouse hippocampal interneurons...
shows a unique dependence on Ca(2+)/calmodulin-dependent kinases.

J Physiol 584:885–894. CrossRef Medline


Marien MR, Colpaert FC, Rosenquist AC (2004) Noradrenergic mecha-


Park CS, Elgersma Y, Grant SG, Morrison JH (2008) Alpha-isoform of calcium-calmodulin-dependent protein kinase II and postsynaptic den-


Sara SJ (2009) The locus coeruleus and noradrenergic modulation of cogni-

senilin 1 prevents amyloid accumulation and temporarily rescues contex-

Selkoe DJ (2008) Soluble oligomers of the amyloid beta-protein impair syn-
aptic plasticity and behavior. Behav Brain Res 192:106–113. CrossRef Medline


Weinshenker D (2008) Functional consequences of locus coeruleus degener-


Yashiro K, Philpot BD (2008) Regulation of NMDA receptor subunit ex-
pression and its implications for LTD, LTP, and metaplasticity. Neuro-
pharmacology 55:1081–1094. CrossRef Medline

